Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Vogenx, Inc./ 8-K

Current Report · Items 8.01 · 8-K

Vogenx, Inc.

Other Events

Item 8.01. Other Events. As previously reported, on August 13, 2026, Vogenx, Inc., a Delaware corporation (the “Company”), consummated its initial public offering (the “Offering”) of 6,250,000 shares of the Company’s common stock, par value $0.0001 per share, at a public offering price of $13.00 per share, generating gross proceeds of $81,250,000.…

Filed Aug 19, 2026Accepted Aug 19, 2026, 4:05 PM EDTCIK 1903784Accession 0001185185-26-003628
View company →Permanent SEC source ↗
Share

Company context

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 22, 2026
  2. 10-Q filingSep 17, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 13, 2026
  4. S-8 filingAug 13, 2026
  5. 424B4 filingAug 12, 2026

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. As previously reported, on August 13, 2026, Vogenx, Inc., a Delaware corporation (the “Company”), consummated its initial public offering (the “Offering”) of 6,250,000 shares of the Company’s common stock, par value $0.0001 per share, at a public offering price of $13.00 per share, generating gross proceeds of $81,250,000. Under the terms of an underwriting agreement dated August 11, 2026 (the “Underwriting Agreement”) by and between the Company and JonesTrading Institutional Services LLC (the “Underwriter”), the Company granted the Underwriter a 45-day option to purchase up to 937,500 additional shares of common stock at the public offering price of $13.00 (the “Over-Allotment Option”). On August 19, 2026, the Company closed on the fully exercised Over-Allotment Option, resulting in additional gross proceeds to the Company of approximately $12,187,500, before deducting underwriting discounts, commissions and offering expenses. After giving effect to the full exercise of the Over-Allotment Option, a total of 7,187,500 shares of common stock have been issued and sold in the Offering, and the gross proceeds from the Offering, including the full exercise of the Over-Allotment Option, before deducting underwriting discounts, commissions and estimated offering expenses, were approximately $93,437,500.